SCHEMBL4760141

SCHEMBL4760141

CCCCn1ncc(C#N)c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.50
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
KDM4E B2RXH2 5/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 2/20 0.40
GRK6 P43250 1/20 0.38
HTT P42858 2/20 0.38
GAA P10253 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
POLB P06746 2/20 0.36
ALDH1A1 P00352 2/20 0.36
RECQL P46063 1/20 0.36
ABL1 P00519 1/20 0.36
KDR P35968 1/20 0.36
XDH P47989 2/20 0.36
F2 P00734 1/20 0.36
KDM5A P29375 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2073708 0.95 PKM (0.49) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL1740693 0.94 PKM (0.48) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL1742738 0.94 PKM (0.48) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL11899586 0.94 PKM (0.48) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL1741752 0.94 PKM (0.48) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL2077595 0.90 PKM (0.53) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL4338327 0.83 KDR (0.40) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL2193196 0.82 PKM (0.55) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL174714 0.81 PKM (0.54) PKMFNTAFNTBKDM4EKMT2A
SCHEMBL2077800 0.80 PKM (0.50) PKMFNTAFNTBKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611766-B2 Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer LOXO ONCOLOGY INC. (US) 2020-04-07 US disclosed
US-10399989-B2 Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer LOXO ONCOLOGY, INC. (US) 2019-09-03 US disclosed
US-7470698-B2 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-12-30 US disclosed
US-20070249641-A1 ADENOSINE A3 RECEPTOR MODULATORS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2007-10-25 US disclosed
US-7271171-B2 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2007-09-18 US disclosed
US-20060040959-A1 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-02-23 US disclosed
US-6921825-B2 Adenosine A3 receptor modulators KING PHARMACEUTICUALS RESEARCH & DEVELOPMENT, INC. (US) 2005-07-26 US disclosed
US-20030144266-A1 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-07-31 US disclosed
US-6448253-B1 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2002-09-10 US disclosed
US-6407236-B1 TUMOR DIAGNOSIS; ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; ANTIDEPRESSANTS MEDCO RESEARCH, INC. 2002-06-18 US disclosed
WO-2000015231-A9 ADENOSINE A3 RECEPTOR MODULATORS MEDCO RES INC (US) 2000-08-17 WO disclosed
CN-1177963-A 6-arylpyrazolo [3, 4-d ] pyrimidin-4-ones and compositions and methods of use thereof SANOFI WINTHROP INC (US) 1998-04-01 CN disclosed
WO-1995001356-A1 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A2 RECEPTOR SCHERING-PLOUGH S.P.A. (IT) 1995-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10611766-B2 Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer BTK, SYK, LCK PKM 1236/4885FNTA 1861/4885FNTB 2656/4885
US-20060040959-A1 Adenosine A3 receptor modulators ADORA3, ADORA2A, ADORA1 PKM 2364/4885FNTA 3516/4885FNTB 3340/4885
US-10399989-B2 Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer BTK, SYK, LCK PKM 1236/4885FNTA 1861/4885FNTB 2656/4885
US-20070249641-A1 ADENOSINE A3 RECEPTOR MODULATORS ADORA3, ADORA2A, ADORA1 PKM 2364/4885FNTA 3516/4885FNTB 3340/4885
US-20030144266-A1 Adenosine A3 receptor modulators ADORA3, ADORA2A, ADORA1 PKM 2552/4885FNTA 3019/4885FNTB 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.